Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486028 · ClinicalTrials.gov registry record
Patient Centered Assessment and Substance Use Disorder Treatment Study (PCAST)
A clinical trial, sponsored by RTI International.
- Completed
- Registry status
- 991
- Enrollment target
NCT03486028: Completed study, sponsored by RTI International.
NCT03486028 is a clinical trial that has completed, run by RTI International. The registered enrollment target is 991 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03486028 has completed, sponsored by RTI International.
- COMPLETED
- Registry status
- 991 participants
- Enrollment target
Study Summary
California counties are in the process of implementing a Centers for Medicare and Medicaid Services Medicaid 1115 Substance Use Disorder (SUD) demonstration. The demonstration requires that patients be assigned to addiction treatment settings and levels of care systematically, using comprehensive biopsychosocial assessments and guided by the American Society of Addiction Medicine (ASAM) patient placement criteria. RTI International, a nonprofit research institute, and University of California Los Angeles (UCLA) Integrated Substance Abuse Programs have been awarded a contract from the Patient Centered Outcomes Research Institute (PCORI) to study the effects of the ASAM implementation in California. The California 1115 SUD demonstration provides a unique opportunity to learn about the benefits and challenges resulting from system-wide implementation of ASAM criteria. The study will involve surveying patients in counties that are using the ASAM criteria and in counties that have not yet adopted the ASAM criteria. Medicaid patients receiving addiction treatment will be offered the opportunity participate in the study and to be surveyed about their experiences in treatment. The study will also analyze data from the California Outcomes Management System (CalOMS) and conduct interviews with providers, patients, and policymakers in the state. The results of the study will help inform California's efforts to continually improve its addiction treatment systems to better meet the needs of it communities. This study will also produce important and useful information to patients seeking treatment for addiction, and their providers, SUD system administrators, and payers.
Primary Outcome
Retention in treatment for at least 14 days is a validated outcome measure and has been shown to be predictive of reduced substance use, 2-year mortality, criminal justice involvement, and detox episodes. Retention in treatment can be measured with the CalOMS data.
Interventions
- OTHER Adherence to ASAM protocols
- OTHER Non-adherence to ASAM protocols
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 991 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2019-10-27 |
What the finished NCT03486028 record still lists
NCT03486028 is an observational study that tracks outcomes without assigning an intervention. The registered 991 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Adherence to ASAM protocols is the first listed.
NCT03486028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03486028 about?
NCT03486028 is a clinical study titled "Patient Centered Assessment and Substance Use Disorder Treatment Study (PCAST)". California counties are in the process of implementing a Centers for Medicare and Medicaid Services Medicaid 1115 Substance Use Disorder (SUD) demonstration. The demonstration requires that patients be assigned to addiction treatment settings and levels of care systematically, using comprehensive bi...
What is the current status of trial NCT03486028?
This trial is currently completed. The enrollment target is 991 participants. The study started on 2018-07-31. Estimated completion is 2019-10-27.
What interventions are being tested in trial NCT03486028?
The interventions under investigation include: Adherence to ASAM protocols (OTHER), Non-adherence to ASAM protocols (OTHER).
Who is sponsoring clinical trial NCT03486028?
This trial is sponsored by RTI International, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI